Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-09
2008-09-09
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
10523020
ABSTRACT:
A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1is H or halogen, R2is OH, or —NR5R6(R5and R6are H or lower alkyl, R3is H, halogen, lower alkyl, or lower alkoxy, R4is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure
REFERENCES:
patent: 5258510 (1993-11-01), Ogawa
patent: 5753677 (1998-05-01), Ogawa
patent: 5827862 (1998-10-01), Yamamura
patent: 2002/0128259 (2002-09-01), Ghazzi et al.
patent: 2003/0008860 (2003-01-01), Bakker-Arkema et al.
patent: 2004/0176354 (2004-09-01), Arkema et al.
patent: A-06-80641 (1994-03-01), None
patent: A-80641 (1994-03-01), None
patent: A-7-188021 (1995-07-01), None
patent: A-8-157368 (1996-06-01), None
patent: A-10-120592 (1998-05-01), None
patent: 11 021241 (1999-01-01), None
patent: WO 94/01113 (1994-01-01), None
patent: WO 01/54677 (2001-08-01), None
L. A. Sorbera et al., “Tolvaptan,” Drugs of the Future, 2002, vol. 27, No. 4, pp. 350-357.
Alberto Martinez-Castelao, OPC-31260 Otsuka, “Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs,” 1999, vol. 1, No. 3, pp. 423-432.
Toshio Nishikimi et al., “Effect of Long-Term Treatment with Selective Vasopressin V1 and V2 Receptor Antagonist on the Development of Heart Failure in Rats,” Journal of Vardiovascular Pharmacology, 1996; vol. 27, No. 2 pp. 275-282.
Keishi Shimizu et al., Effects of Oral OPC-31260, a Vasopressin V2-Receptor Antagonist Administration on Arterial Baroreceptor Reflex in Conscious Intact and Adriamycin-Induced Heart Failure Rats, Naika Hokan, 1993, vol. 40, No. 1, pp. 7-11.
Louise M. Burrell et al., Long-Term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat, American Journal of Physiology, 1998, vol. 275, No. 1, pp. H-176-H182.
Mareo Naitoh et al., Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure In conscious dogs, American Journal of Physiology, 1994, vol. 267, No. 6, Part 2, pp. H2245-H2254.
Taresh Taneja et al., “Current Status of Acute Intravenous Therapy for Chronic Heart Failure Exacerbations,” CHF Sep./Oct. 1999, pp. 199-207, 215.
Leonard Arnolda et al., “Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure,” Cardiovascular Research 1991; 25: pp. 68-72.
Mihai Gheorghiade et al., “Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure,” American Heart Journal, vol. 145, No. 2, Feb. 2003; pp. S51-4.
C, Serradeil-Le Gal et al., “Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2and V1breceptor ligands,” Progress in Brain Research, vol. 139, 2002, pp. 197-210.
Louise M. Burrell et al., “Vasopressin receptor antagonism—a therapeutic option in heart failure and hypertension,” Experimental Physiology, Mar. 2000; 85 Spec; pp. 259S-265S.
Yoshitaka Yamamura et al., “OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats,” The Journal of Pharmacology and Experimental Therapeutics, Dec. 1998, vol. 287, No. 3, pp. 860-867.
B. Mayinger et al., “Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene, Experimental and Clinical Endocrinology & Diabetes,” 1999, vol. 107; pp. 157-165.
Mareo Naitoh et al., “Effects of Chronic AVPV2R Blockade in Congestive Heart Failure in Sheep,” Vasopressing and Oxytocin, Adv Exp Med Biol. 1998; 449, pp. 445-446.
Chagriya Kitiyakara et al., Vasopressin V2-receptor antagonists: panaceas for hyponatremia?, Current Opinion in Nephrology and Hypertension, Sep. 1997, vol. 6, No. 5, pp. 461-467.
Ding-Li Xu et al., “Upregulation of Aquaporin-2 Water Channel Expression in Chronic Heart Failure Rat,” The American Society for Clinical Investigation, Inc. Apr. 1997, vol. 99, No. 7, pp. 1500-1505.
J. G. Verbalis, “Vasopressin V2receptor antagonists,” Journal of Molecular Endocrinology, 2002, vol. 29, pp. 1-9.
J. Donald Albright et al., “Recent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide V1aand V2Receptor Antagonists,” Current Pharmaceutical Design, vol. 3, pp. 615-632.
Junkankika 41, 150-154, 1997.
Gheorghiade Mihai et al., “Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized double-blind trial,” Circulation, vol. 102, No. 18Supplement, Oct. 31, 2000, pp. II.592.
Patent Abstracts of Japan, vol. 1999, No. 4, Apr. 30, 1999 & JP 11 021241 A, Otsuka Pharmaceuticals Co., Ltd., Jan. 26, 1999, Abstract.
Supplementary European Search Report, issued in EP 04 71 3672, Feb. 3, 2006.
Communication from European Patent Office issued in Application No. 04 713 672.6—2123, dated May 29, 2007, 6 pages.
Russia Office Action dated Dec. 13, 2007, Application No. 2005102110/14(002682).
V.A. Galkin, “Polyclinical therapy”, Moscow, “Medicine”, 2000, pp. 117-120.
V.G. Belikov, “Pharmaceutical chemistry”, Moscow, “High school”, 1993, vol. 1, pp. 43-47.
Maki Yosuke
Ozaki Atsushi
Sato Osamu
Yamamura Yoshitaka
Henley, III Raymond J
Otsuka Pharmaceutical Co. Ltd.
LandOfFree
Method for treating severe heart failure and medicament... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating severe heart failure and medicament..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating severe heart failure and medicament... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3923478